Leslie M. Randall

picture of Leslie M. Randall

Associate Professor, Obstetrics & Gynecology
School of Medicine

Director, Medical Education in Gynecologic Oncology

Director, Fellowship in Gynecologic Oncology

M.D., University of Louisville School of Medicine, 2001

Phone: (714) 456-7971
Email: lrandall@uci.edu

University of California, Irvine
333 City Boulevard West
Suite 1400
Mail Code: 3200
Orange, CA 92868
Research Interests
Novel therapeutics for the treatment of gynecologic cancers and markers of treatment efficacy and/or resistance with a focus on anti-angiogenesis and PARP inhibition
Academic Distinctions

Clymer Medical Scholarship (Full-Tuition, Annually Renewed)

Cum Laude
University of Louisville School of Medicine
Louisville, KY

Who’s Who Among American Medical Schools

Samuel S. Gordon Award in Obstetrics and Gynecology

Endocrine Society Award for Outstanding Medical Student in Reproductive
Endocrinology and Infertility (National Award)

Dr. Tom Lee Carter Award for Outstanding Academic Achievement by a Medical Student from a Medically Underserved Area


Ortho-McNeil Award for Highest Council for Residency Education in Obstetrics and Gynecology (CREOG) Exam Score in Second-Year Resident Class
Department of Obstetrics and Gynecology
University of Louisville School of Medicine
Louisville, KY

Ortho-McNeil Award for Highest CREOG Exam Score in Third-Year Resident Class
Department of Obstetrics and Gynecology
University of Louisville School of Medicine
Louisville, KY

Ortho-McNeil Award for Highest CREOG Exam Score in Chief-Resident Class
Department of Obstetrics and Gynecology
University of Louisville School of Medicine
Louisville, KY

Golden Hands Award for Most Surgically-Proficient Resident
Department of Obstetrics and Gynecology
University of Louisville School of Medicine
Louisville, KY


Finalist, American Association of Obstetricians & Gynecologists Foundation and American Board of Obstetrics and Gynecology (AAOGF/ABOG) Research Scholarship

American Association of Cancer Research/American Society of Clinical Oncology Workshop: Methods in Clinical Cancer Research
Vail CO

Orange County Medical Association Physicians of Excellence

Recipient, AAOGF/ABOG Research Scholarship (Three-year career development award)

Southern California Super Doctors Rising Stars

Gynecologic Oncology Group (GOG) New Investigator Award

UC Irvine Health ARI2SE Recognition Award for Respect

American Gynecologic and Obstetrical Society (AGOS) Presidential Travel Award

Society of Gynecologic Oncology (SGO) Representative to National Multidisciplinary Summit on Gynecologic Cancer Genetics

Associate Professor of Clinical Obstetrics and Gynecology
Division of Gynecologic Oncology
University of California, Irvine

Director, Fellowship in Gynecologic Oncology
University of California, Irvine

Director of Medical Education in Gynecologic Oncology
University of California, Irvine


Associate Director, Fellowship in Gynecologic Oncology
University of California, Irvine

Assistant Professor of Clinical Obstetrics and Gynecology
Division of Gynecologic Oncology
University of California, Irvine

Health Sciences Clinical Instructor
Department of Obstetrics and Gynecology
University of California, Irvine

1. Randall-Whitis L, Monk BJ. Metastatic cervical cancer: Options for further treatment. In: Dizon D and Abu-Rustum N, eds. Gynecologic Cancer: Evidence-Based Multidisciplinary Management. Jones and Bartlett Publishers, Sudbury, MA. 2009.

2. Randall L. Managing Recurrent Disease. In: Bristow RE and Cornelison T, eds. In press.

1. Ford CL, Randall-Whitis L, Ellis SR. Yeast proteins related to the p40/laminin receptor precursor are required for 20S ribosomal RNA processing and the maturation of 40S ribosomal subunits. Cancer Research. 59(3): 704-10. Feb. 1999.

2. Randall-Whitis L, Taylor DD, Gercel-Taylor C. cDNA microarray analysis of gene expression in ovarian cancer cells after treatment with carboplatin and paclitaxel. Cancer Genomics and Proteomics 3:289-294, 2006.

3. Randall-Whitis L. Monk BJ. Topotecan in the management of cervical cancer. Expert Opinion on Pharmacotherapy 8(2):227-36, 2007. Review.

4. Helm CW, Randall-Whitis L, Martin RS 3rd, Metzinger DS, Gordinier ME, Parker LP, Edwards RP. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol. 105(1):90-6, 2007. PubMed PMID: 17173957.

5. American College of Obstetrics and Gynecology. (Randall-Whitis L and Berman ML) Management of Adnexal Masses. ACOG Practice Bulletin #83. Obstetrics and Gynecology 109: July 2007.

6. Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol. . Gynecol Oncol. 2009 Mar;112(3):583-9. PubMed PMID: 19110305; PubMed Central PMCID: PMC2858218.

7. Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbidge EJ. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2010 Mar;116(3): 452-
8. PubMed PMID: 19913895; PubMed Central PMCID: PMC2822024

8. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010 Jun;117(3):497-504. Review. PMID: 20363017.

9. Randall LM, Monk BJ, Moon J, Parker R, Al-Ghazi M, Wilczynski S, Fruehauf JP, Markman M, Burger RA. Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: A Southwest Oncology Group Study. Gynecol Oncol. 2010 Dec;119(3):417-21. PMID: 20846714; PubMed Central PMCID: PMC2978536.

10. Moniaga NC, Randall LM. Malignant Mixed Ovarian Germ Cell Tumor with Embryonal Component. J Pediatr Adolesc Gynecol. 2011 Feb;24(1):e1-3. PMID: 20869284.

11. Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol. 2010 Dec;119(3):484-90 PMID: 20870280; PubMed Central PMCID: PMC2975758.

12. Jordan S, Randall LM, Karamurzin Y, Ward P, Lin F, Brewster W, Monk BJ. Differentiating squamous cell carcinoma of the cervix and epithelioid trophoblastic tumor. Int J Gynecol Cancer. 2011 Jul; 21(5):918-22. PubMed PMID: 21697681.

13. Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011 Aug;205(2):103-10.PubMed PMID: 21411052.

14. Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics. 2011;5:1-5. PubMed PMID: 21383911; PubMed Central PMCID: PMC3044789

15. Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2012 Mar; 124(3):563-8. PubMed PMID: 22138229; PubMed Central PMCID: PMC3278517.

16. Eskander RN, Randall LM, Sakai T, Guo Y, Hoang B, Zi X. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J Obstet Gynaecol Res. 2012 Aug;38(8):1086-94. PubMed PMID: 22540374; PubMed Central PMCID: PMC3405181.

17. Pinn-Bingham M, Puthawala AA, Syed AM, Sharma A, Disaia P, Berman M, Tewari KS, Randall-Whitis L, Mahmood U, Ramsinghani N, Kuo J, Chen WP, McLaren CE. Outcomes of high-dose rate interstitial brachytherapy in the treatment of locally advanced cervical cancer: long-term results. Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):714-20. PubMed PMID: 22763030.

18. Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B. Inhibition of Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated With Decreased Tumor Cell Proliferation, Migration, and Invasion in Endometrial Cancer Cell Lines. Int J Gynecol Cancer. 2013 Jul;23(6):997-1005. PubMed PMID: 23792601

19. Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H. High-volume ovarian cancer care: Survival impact and disparities in access for advanced-stage disease. Gynecol Oncol. 2013 Dec 20. pii: S0090-8258(13)01381-4. doi: 10.1016/j.ygyno.2013.12.017. PubMed PMID: 24361578.

20. Liu FW, Randall LM, Tewari KS, Bristow RE. Racial disparities and patterns of ovarian cancer surgical care in California. Gynecol Oncol. 2014 Jan;132(1):221-6. PubMed PMID: 24016407.

21. Krill LS, Adelson JW, Randall LM, Bristow RE. Clinical commentary: Medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using a non-bevacizumab containing arm feasible in patients with recurrent cervical cancer? Gynecol Oncol. 2014 Jun 27.

22. Randall LM, Gibson SJ, Monk BJ. The American Society of Clinical Oncology 50th Annual Meeting 2014: an overview and summary of selected abstracts. Gynecol Oncol. 2014 Aug;134(2):222-7. doi: 10.1016/j.ygyno.2014.07.086. PubMed PMID: 25090931.

23. Eskander RN, Ali S, Dellinger T, Lankes HA, Randall LM, Ramirez NC, Monk BJ, Walker JL, Eisenhauer E, Hoang BH. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2016 Jan;26(1):125-32. doi: 10.1097/IGC.0000000000000563. PubMed PMID: 26397159.

24. Westin SN, Randall L. The European Society of Gynecologic Oncology (ESGO) 19th biannual meeting: Overview and summary of selected topics. Gynecol Oncol. 2016 Mar;140(3):377-80. doi: 10.1016/j.ygyno.2016.01.021. Epub 2016 Jan 22. PubMed PMID: 26807487.

25. Randall LM, Pothuri B. The genetic prediction of risk for gynecologic cancers. Gynecol Oncol. 2016 Apr;141(1):10-6. doi: 10.1016/j.ygyno.2016.03.007. PubMed PMID: 27016223.

1. Randall-Whitis L. In the first person. Editorial. Fall Bulletin of the Gynecologic Cancer Foundation. August 2004.

2. Randall-Whitis L, DiSaia PJ. In the Hot Seat: Hormone Therapy following Breast Cancer. The Female Patient 32(2), 2007.

3. Randall, LM, Monk, BJ. Update on anti-angiogenesis therapy for ovarian and cervical cancers.
Contemporary OB/GYN. Featured Topic (2-7), July 2009.
Title: A phase 1 dose-escalation and pharmacokinetic (PK) study of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) carboplatin at the time of cytoreductive surgery for the initial treatment of advanced ovarian, fallopian tube, and peritoneal carcinomas Funding Source: Seed Funding from NIH Cancer Center Support Grant (P30CA062203) Duration: 1/1/14-12/31/15 Role: Recipient and PI
Title: A randomized, open-label, multicenter, phase 2 trial evaluating the safety and activity of DNIB0600A compared to pegylated liposomal doxorubicin administered intravenously to patients with platinum-resistant ovarian cancer. Funding Source: PPD Inc. Duration: 12/02/13- 06/01/16 Role: PI
Title: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum Funding Source: ARRAY BIOPHARMA INC. Duration: 12/01/13- 11/30/16 Role: PI
Title: Phase 2 Prospective, Open-Label Study to Investigate the Intra-operative Detection of Folate Receptor-alpha Positive Ovarian Cancer Using Folate-FITC (EC17) Funding Source: On Target Laboratories, LLC. Duration: 8/01/13- 7/30/14, pending activation of follow-up study Role: PI
Title: The American Board of Obstetrics and Gynecology Educational Foundation/ American Association of Obstetricians and Gynecologists Foundation (ABOG/AAOGF) Scholarship Funding Source: ABOG/AAOGF Duration: 7/1/2013-6/30/16 Role: Recipient/PI
Title: Loan Repayment Program Funding Source: NIH Duration: 9/1/10-8/31/12, 9/1/14-8/31/15, pending renewal Role: Recipient
Title: 5P30CA062203-15 Meyskens (PI) Development Funds-This program award provides funding for salary support and start-up funds for a junior faculty member at UC Irvine selected through a competitive process. Funding Source: NIH Duration: 09/30/09-09/29/11 Role: Recipient
Title: UCI 04-33 - An Open-Label, Single-Arm, Phase 2 Study of IV Weekly (Days 1 and 8 every 21 Days topotecan in Combination with Carboplatin (Day 1 every 21 Days) as Second-Line Therapy in Subjects with Potentially Platinum-Sensitive Relapsed Ovarian Cancer Funding Source: Glaxo Smith Kline Duration: 05/12/05-04/24/10 Role: PI
Title: UCI 06-43 - Phase 2 Trial of Pazopanib in Combination with Lapatinib Compared to Pazopanib and Lapatinib in FIGO Stage IVB, Recurrent or Persistent Cervical This is a three-arm, randomized, phase 2 trial exploring the efficacy and safety of the three regimens for women with metastatic, recurrent, or persistent Cervical Cancer Funding Source: Glaxo Smith Kline Duration: 04/01/07-03/31/10 Role: PI
Title: OX-04-064 - The goal of this study is to determine differential response of cervical cancer cell lines to various in vitro chemotherapy regimens that contain either oxaliplatin or cisplatin. Funding Source: Sanofi-Aventis Duration: 10/20/06-10/19/11 Role: Co-PI
Title: UCI 05-61 - Pilot Phase 2 Study Evaluating the Combination of Oxaliplatin and Docetaxel with Bevacizumab as First Line Therapy in Pts with FIGO Stage IB-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma. Funding Source: Rho Inc Duration: 06/14/06-08/31/11 Role: PI
Title: UCI 09-30 - Phase 2 Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis) in Patients with Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated with One Line of Systemic Chemotherapy Funding Source: Pharma Mar SA Duration: 10/13/09-06/30/12 Role: PI
Title: UCI 09-18 - Phase 3 Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy vs Placebo in Women Who Have Not Progressed After First-Line Chemo for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Funding Source: Glaxo Smith Kline Duration: 07/21/09-01/07/15 Role: PI
Title: University of California Irvine Chao Family Comprehensive Cancer Center Ovarian Cancer Awareness Symposium Funding Source: California Ovarian Cancer Awareness Program (COCAP) Duration: 1/1/10-7/1/10 Role: PI
Title: University of California Irvine Chao Family Comprehensive Cancer Center Ovarian Cancer Awareness Symposium Funding Source: California Ovarian Cancer Awareness Program (COCAP) Duration: 1/1/12-7/1/12 Role: PI
Title: UCI 11-70 - Phase 1/2 Study Evaluating lntermittent & Continuous OSI-906 & Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer and other Solid Tumors Funding Source: Astellas Foundation Duration: 6/28/12-6/27/15 Role: PI
Title: A Phase 1-2 Study of Onapristone in Patients with Progesterone Receptor Expressing Cancers. Funding Source: ARNO Therapeutics, Inc. Duration: 11/20/15 – 11/29/20 Role: Site PI
Title: An Open Label Phase 1/2 Dose Escalation Study Evaluation The Safety And Tolerability Of GDC-0032 In Patients With Locally Advanced Or Metastatic Solid Tumors Or Non-Hodgkins Lymphoma And In Combination With Endocrine Therapy In Patients With Locally Advanced Or Metastatic Hormone Receptor Positive Breast Cancer. Funding Source: Genentech, Inc Duration: 12/18/15 – 10/13/16 Role: Site PI
Professional Societies
Member, American Medical Association
Junior Fellow, American College of Obstetricians & Gynecologists (ACOG)
Member, Endocrine Society
Member, Kentucky Medical Association
Member, Jefferson County Medical Association
Member, Louisville Obstetrics & Gynecology Society
Fellow-in-Training, Society of Gynecologic Oncology (SGO)
Fellow-in-Training, American Society of Clinical Oncologists
Candidate Member, SGO
Active Member, ASCO
Member, International Gynecologic Cancer Society (IGCS)
Full Member, SGO
Fellow, American College of Surgeons
Member, Academy for Innovation in Medical Education (AIME)
Other Experience
Candidate Member
SGO Marketing and Communications Committee 2009—curr

UC Irvine Chao Family Comprehensive Cancer Center Data Safety Monitoring Board 2010—curr

Program Committee, 2012 SGO Annual Meeting on Women’s Cancer 2011—2012

UC Irvine Biomedical Institutional Review Board (IRB B) 2011—2015

Vice Chair and Chair-Elect
SGO Communications Committee 2013—2014

Department of Obstetrics and Gynecology Clinical Competency Committee 2014—curr

Active Investigator #45405
National Cancer Institute 2009—curr

Voting Member
Developmental Therapeutics Committee, Gynecologic Oncology Group National Cancer Institute 2009—curr

Co-Principal Investigator
UC Irvine Gynecologic Oncology Group 2010—curr

Medical Advisory Board, Ovarian Cancer Orange County Alliance 2010—curr

Director of Medical Education
UC Irvine Gynecologic Oncology 2011—curr

UC Irvine Chao Family Comprehensive Cancer Center Women’s Disease Oriented Research Team 2012—curr

Voting Member
Ovarian Cancer Committee, NRG (Legacy GOG) 2014—curr

SGO Joint Stakeholder Summit on Genetic Testing in Gynecologic Oncology 2015

Vice Chair
UC Irvine Biomedical Institutinal Review Board (IRB A) 2015—2016

SGO and Foundation for Women's Cancer (FWC) Communications Committee 2016—curr

Last updated